Nurix announced the first patient dosing in a registrational Phase 3 trial for bexobrutideg and received a $700 million upfront payment from Roche, bolstering cash reserves to $1.1 billion.
Nurix announced the first patient dosing in a registrational Phase 3 trial for bexobrutideg and received a $700 million upfront payment from Roche, bolstering cash reserves to $1.1 billion.